Trop-2 is a novel target for solid cancer therapy with...

Oncotarget 2015 / 09 Vol. 6; Iss. 26

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Goldenberg, David M., Cardillo, Thomas M., Govindan, Serengulam V., Rossi, Edmund A., Sharkey, Robert M.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
6
Language:
english
Journal:
Oncotarget
DOI:
10.18632/oncotarget.4318
Date:
September, 2015
File:
PDF, 5.11 MB
english, 2015
Conversion to is in progress
Conversion to is failed